FRONTIER
1850  Management of obstructive colon cancer: Current status, obstacles, and future directions
Yoo RN, Cho HM, Kye BH

REVIEW
1863  Role of endoscopic ultrasound in anticancer therapy: Current evidence and future perspectives
Bratanic A, Bozic D, Mestrovic A, Martinovic D, Kumrić M, Ticinovic Kurir T, Bozic J

1880  Pancreatic intraductal papillary mucinous neoplasms: Current diagnosis and management
Jabłońska B, Szmigiel P, Mrowiec S

1896  Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?

1919  Unique situation of hepatocellular carcinoma in Egypt: A review of epidemiology and control measures
Ezzat R, Eltabbakh M, El Kassas M

1939  Moving forward in the treatment of cholangiocarcinoma

1956  Solid extraintestinal malignancies in patients with inflammatory bowel disease
Mala A, Foteinogiannopoulou K, Koutroubakis IE

1981  Mesenchymal stem cell-derived exosomes for gastrointestinal cancer
Zhao LX, Zhang K, Shen BB, Li JN

1997  Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer

2013  Macrophages play a role in inflammatory transformation of colorectal cancer
Lu L, Liu YJ, Cheng PQ, Hu D, Xu HC, Ji G

MINIREVIEWS
2029  Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
Dai K, Wu Y, She S, Zhang Q

2038  Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma
Alqahtani SA, Colombo MG
Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?

Current status of non-surgical treatment of locally advanced pancreatic cancer

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy

Dysbiosis of the duodenal microbiota as a diagnostic marker for pancreaticobiliary cancer

MutL homolog 1 methylation and microsatellite instability in sporadic colorectal tumors among Filipinos
Cabral LKD, Mapua CA, Natividad FF, Sukowati CHC, Cortez ER, Enriquez MLD

Propofol induces ferroptosis and inhibits malignant phenotypes of gastric cancer cells by regulating miR-125b-5p/STAT3 axis
Liu YP, Qiu ZZ, Li XH, Li EY

BRAF \textsuperscript{V600E} mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs
Zhi J, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT

Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients

Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy
Liu ZN, Wang YK, Zhang L, Jia YN, Fei S, Ying XJ, Zhang Y, Li SX, Sun Y, Li ZY, Ji JF

Clinical features of intracerebral hemorrhage in patients with colorectal cancer and its underlying pathogenesis
Deng XH, Li J, Chen SJ, Xie YJ, Zhang J, Cen GY, Song YT, Liang ZJ

Anatomic resection improved the long-term outcome of hepatocellular carcinoma patients with microvascular invasion: A prospective cohort study
Zhou JM, Zhou CY, Chen XP, Zhang Zw
### Systematic Reviews

**2203** Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review  

### Letter to the Editor

**2216** Gender differences in the relationship between alcohol consumption and gastric cancer risk are uncertain and not well-delineated  
*Verma HK, Bhaskar L*

**2219** Critical biomarkers of hepatocellular carcinoma in body fluids and gut microbiota  
*Nath LR, Murali M, Nair B*
ABOUT COVER
Editorial Board Member of World Journal of Gastrointestinal Oncology, Ladan Teimoori-Toolabi, MD, PhD, Associate Professor, Department of Molecular Medicine, Pasteur Institute of Iran, Tehran 1316943551, Iran. iteimoori@pasteur.ac.ir

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Reports® cites the 2020 impact factor (IF) for WJGO as 3.393; IF without journal self cites: 3.333; 5-year IF: 3.519; Journal Citation Indicator: 0.5; Ranking: 163 among 242 journals in oncology; Quartile category: Q3; Ranking: 60 among 92 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2020 is 3.3 and Scopus CiteScore rank 2020: Gastroenterology is 70/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon M Kasi, Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
December 15, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc
Basic Study

Propofol induces ferroptosis and inhibits malignant phenotypes of gastric cancer cells by regulating miR-125b-5p/STAT3 axis

Yi-Ping Liu, Zhong-Zhi Qiu, Xu-Hui Li, En-You Li

ORCID number: Yi-Ping Liu 0000-0001-9992-8789; Zhong-Zhi Qiu 0000-0001-5463-7646; Xu-Hui Li 0000-0002-7887-4440; En-You Li 0000-0001-9594-2508.

Author contributions: Liu YP and Qiu ZZ designed the study; Liu YP and Li XH performed the experiments; Qiu ZZ collected and analyzed data; Li EY wrote the manuscript.

Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Harbin Medical University.

Institutional animal care and use committee statement: All animal experiments were performed under the approval of Animal Ethics Committee of The First Affiliated Hospital of Harbin Medical University.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: No additional data are available.

ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised.

Abstract

BACKGROUND
Gastric cancer is a common malignancy with poor prognosis, in which ferroptosis plays a crucial function in its development. Propofol is a widely used anesthetic and has antitumor potential in gastric cancer. However, the effect of propofol on ferroptosis during gastric cancer progression remains unreported.

AIM
To explore the function of propofol in the regulation of ferroptosis and malignant phenotypes of gastric cancer cells.

METHODS
MTT assays, colony formation assays, Transwell assays, wound healing assay, analysis of apoptosis, ferroptosis measurement, luciferase reporter gene assay, and quantitative reverse transcription polymerase chain reaction were used in this study.

RESULTS
Our data showed that propofol was able to inhibit proliferation and induce apoptosis of gastric cancer cells. Meanwhile, propofol markedly repressed the invasion and migration of gastric cancer cells. Importantly, propofol enhanced the erastin-induced inhibition of growth of gastric cancer cells. Consistently, propofol increased the levels of reactive oxygen species, iron, and Fe^{2+} in gastric cancer cells. Moreover, propofol suppressed signal transducer and activator of transcription (STAT)3 expression by upregulating miR-125b-5p and propofol induced ferroptosis by targeting STAT3 in gastric cancer cells. The miR-125b-5p inhibitor or STAT3 overexpression reversed propofol-attenuated malignant phenotypes of gastric cancer cells.
CONCLUSION

Propofol induced ferroptosis and inhibited malignant phenotypes of gastric cancer cells by regulating the miR-125b-5p/STAT3 axis. Propofol may serve as a potential therapeutic candidate for gastric cancer.

Key Words: Gastric cancer; Progression; Ferroptosis; Propofol; miR-125b-5p; STAT3

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: In this study, we discovered that propofol induced ferroptosis and inhibited malignant phenotypes of gastric cancer cells by regulating the miR-125b-5p/STAT3 axis. Propofol may serve as a potential therapeutic candidate for gastric cancer.

INTRODUCTION

Gastric cancer is a severe, lethal type of cancer worldwide [1]. Despite improvement in treatment, gastric cancer remains the leading cause of cancer-associated death [2]. Adjuvant therapy, radical surgery, and early diagnosis enhance survival rates and prognosis for gastric cancer, but mortality is still unsatisfactory [3, 4]. Ferroptosis is a type of regulated cell death that differs from apoptosis and is repressed by erastin, especially in RAS-mutated cancer cells [5]. It has been identified that the suppression of ferroptosis contributes to cancer progression, and ferroptosis has a crucial role in the development of gastric cancer [6-8]. However, the exploration of a treatment that can target ferroptosis is still limited.

Propofol is a broadly applied anesthetic because of rapid recovery and has some nonanesthetic functions in cancer development [9]. It has been identified that propofol inhibits cell invasion and growth and induces apoptosis in pancreatic cancer [10]. Meanwhile, propofol decreases cell proliferation and increases apoptosis of lung cancer cells by regulating caspases-3, Bim, forhead box (FOX)O1, and FOXO3, in which miR-486 inhibitor can reverse this effect [11]. Propofol also represses the malignant progression of promyelocytic leukemia cells [12]. Moreover, it has been reported that propofol induces an inhibitory effect on gastric cancer cell invasion and migration in patients with gastric cancer [13, 14]. However, the function of propofol in the modulation of ferroptosis during gastric cancer progression remains elusive. miRNAs can modulate gene expression in different cellular processes [15]. Previous studies have revealed that miRNAs participate in the development of gastric cancer [16, 17]. Meanwhile, a recent study has shown that miR-125b-5p is a tumor suppressor and involved in the modulation of gastric cancer [18]. In addition, signal transducer and activator of transcription (STAT)3 has been identified as an oncogene in gastric cancer [19-21]. However, the effect of propofol on miR-125b-5p and STAT3 during the development of gastric cancer remains obscure.

In this study, we focused on the investigation of the function of propofol in the development of gastric cancer. We found that propofol induced ferroptosis and inhibited malignant phenotypes of gastric cancer cells by regulating the miR-125b-5p/STAT3 axis.

MATERIALS AND METHODS

Cell culture

The SGC7901 and BGC823 cells were maintained in the laboratory. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Solarbio, China) with 0.1 mg/mL streptomycin (Solarbio), 100 U/mL penicillin (Solarbio), and 10% fetal bovine...
serum (Solarbio), under the conditions of 37 °C with 5% CO₂. The pcDNA3.1-STAT3 overexpression vector, miR-125b-5p mimic, miR-125b-5p inhibitor, and corresponding control were purchased from Genescript Biotech Corporation (Nanjing, China) and GenePharma Co. Ltd. (Shanghai, China). The transfection in the cells was performed by Liposome 3000 (Invitrogen, Carlsbad, CA, United States). Propofol was purchased from Sigma (St. Louis, MO, United States).

**MTT assays**
SGC7901 and BGC823 cells were treated with propofol for 48 h. MTT assays analyzed the proliferation of SGC7901 and BGC823 cells. About 2 × 10⁵ cells were plated in 96-well plates and incubated for 24 h. To assess cell viability, the cells were cultured with MTT solution (5 mg/mL) and incubated for 4 h, and 150 μL dimethyl sulfoxide (DMSO) was applied to treat the cells. The cell viability was measured at 570 nm absorbance by applying an ELISA browser (Bio-Tek EL 800, Winooski, VT, United States).

**Colony formation assays**
The SGC7901 and BGC823 cells were treated with propofol for 48 h. Colony formation assays measured proliferation. About 10⁴ SGC7901 and BGC823 cells were placed in six-well plates and cultured in DMEM at 37 C. The cells were cleaned with phosphate-buffered saline (PBS) after 2 wk, washed in methanol for ~30 min, and stained with 1% crystal violet dye, after which, the number of colonies was calculated.

**Transwell assays**
To analyze cell migration, the cells were cultured for 24 h and resuspended in serum-free culture medium, then plated into the apical chamber of a Transwell chamber at 5 × 10³ cells/well. The culture medium was made up to 150 μL and 600 μL complete culture medium was added to the basolateral chamber. After 24 h culture at 37°C and 5% CO₂ the cells were fixed with 4% paraformaldehyde for 10 min, stained by crystal violet dye for 20 min, followed by analysis using the intelligent biological navigator (Olympus, Tokyo, Japan). The migrated cells were recorded and calculated by using the ImageJ software.

**Wound healing assay**
SGC7901 and BGC823 cells were treated with propofol for 48 h. Approximately 3 × 10⁶ SGC7901 and BGC823 cells were plated into the 24-well plates and incubated overnight to reach a fully confluent monolayer. A 20-μL pipette tip was applied to slowly cut a straight line across the well. The well was washed by PBS three times and the medium was changed to serum-free medium and culture was continued. The wound healing percentage was calculated.

**Analysis of apoptosis**
The SGC7901 and BGC823 cells were treated with propofol for 48 h. Approximately 2 × 10⁶ SGC7901 and BGC823 cells were plated in six-well dishes. Apoptosis was determined using the Annexin V-FITC Apoptosis Detection Kit (Cell Signaling Technology, Danvers, MA, United States). About 2 × 10⁶ washed cells were collected by binding buffer and stained at 25°C, followed by flow cytometry analysis.

**Ferroptosis measurement**
SGC7901 and BGC823 cells were cotreated with erastin (5 mmol/L) or ferrostatin (1 mmol/L). After 48 h, the cell viability was analyzed by MTT assay. Elevated iron level and accumulated lipid reactive oxygen species (ROS) were representative characteristics of ferroptosis. We used an iron assay kit (Beyotime, China) to examine the level of intracellular Fe²⁺. The cells were homogenized to collect the supernatant, incubated with iron reducer, followed by labeling with iron probe. OD 590 nm was detected in a microplate reader (PerkinElmer, Waltham, MA, United States). For detection of lipid
ROS, cells were stained with BODIPY C-11 dye (Beyotime) for 30 min, and subsequently detected by flow cytometry (BD Biosciences, Franklin Lakes, NJ, United States). The levels of malondialdehyde (MDA) and glutathione peroxidase (GSH) was measured by the MDA detection kit (Beyotime) and GSH assay kit (Cayman, Ann Arbor, MI, United States), respectively.

**Luciferase reporter gene assay**

The luciferase reporter gene assays were performed using the Dual-luciferase Reporter Assay System (Promega, Madison, WI, United States). SGC7901 and BGC823 cells were treated with miR-125b-5p mimic, pmirGLO-STAT3 (contained STAT3 3’UTR), and pmirGLO-STAT3 mutant transfected into the cells using Lipofectamine 3000 (Invitrogen), followed by analysis of luciferase activities, in which Renilla was applied as a normalized control.

**Quantitative reverse transcription polymerase chain reaction**

Total RNA was extracted by TRIZOL (Invitrogen). The first-strand cDNA was manufactured according to the manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, United States). qRT-PCR was carried out by SYBR Real-time PCR kit (Takara, Japan). The standard control for miRNA and mRNA/circRNA was U6 and GAPDH, respectively. Quantitative determination of the RNA levels was conducted in triplicate independent experiments. The primer sequences were as follows: miR-125b-5p forward: 5'-TCCCTGAGACCCCTAACTTGTGA-3'; reverse: 5'-AGTCTCAGGGTCGAGGTATTC-3'; STAT3 forward: 5'-GGCCATCTTGAGCACTAAGC-3', reverse: 5'-CGGACTGGATCTGGGTCTTA-3'; GAPDH forward: 5'-TATGATGATATCAAGAGGGTAGT-3'; U6 forward: 5'-CTCGCTTCGGCAGCACA-3', U6 reverse: 5'-AACGCTTCAGAATT TGCGT-3'.

**Western blot analysis**

Total proteins were isolated from the cells with RIPA buffer (Cell Signaling Technology) and analyzed by BCA Protein Quantification Kit (Abbkine, United States). The protein was separated by 12% SDS-PAGE, and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA, United States). The membranes were treated with 5% milk and incubated overnight at 4°C with the primary antibodies for STAT3 (Rabbit monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology), GPX4 (Rabbit monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology) and SLC7A11 (Rabbit monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology); and β-actin (Mouse monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology), E-cadherin (Rabbit monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology) and vimentin (Rabbit monoclonal, 1:1000, diluted by 5% milk; Cell Signaling Technology), in which β-actin served as the control. The corresponding secondary antibodies (Abcam, Cambridge, MA, United States) were incubated with the membranes for 1 h at room temperature, followed by visualization using an Odyssey CLx Infrared Imaging System.

**Xenograft assays**

All animal experiments were performed under the approval of Animal Ethics Committee of The First Affiliated Hospital of Harbin Medical University. Specific-pathogen-free male nude mice aged 5-6 wk and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-h circadian rhythm, and had free access to water and food. SGC7901 and BGC823 cells were subcutaneously injected into the right flank of mice. Propofol (50 mg/kg/d) was administrated intraperitoneally after tumor volume approached 100 mm$^3$ for 20 d[22]. For the control group, the mice were treated with an equal volume of DMSO. Tumor volume and body weight were monitored every 5 d. The tumor size was calculated using the formula: length × width$^2$/2.

**Statistical analysis**

Data were expressed as mean ± SD, and the statistical analysis was conducted using GraphPad Prism 7. The unpaired Student’s $t$ test was used to compare two groups, and one-way analysis of variance was used to compare among multiple groups. $P < 0.05$ was considered statistically significant.
RESULTS

Propofol decreases proliferation and induces apoptosis of gastric cancer cells
We evaluated the effect of propofol on proliferation and apoptosis of gastric cancer cells. Propofol repressed viability of SGC7901 and BGC823 cells in a dose-dependent manner and 10 µmol/L propofol had a greater effect, which was selected in the subsequent analysis (Supplementary Figure 1). Propofol was able to inhibit viability of SGC7901 and BGC823 cells (Figure 1A and B). Similarly, propofol markedly reduced proliferation of SGC7901 and BGC823 cells (Figure 1C and D). Apoptosis of SGC7901 and BGC823 cells was enhanced by propofol (Figure 1E and F), suggesting that propofol decreases proliferation and induces apoptosis of gastric cancer cells.

Propofol reduces invasion and migration of gastric cancer cells
We further investigated the role of the propofol/miR-125b-5p/STAT3 axis in gastric cancer. Transwell assays indicated that the migration and invasion of SGC7901 and BGC823 cells were markedly decreased by propofol (Figure 2A and B). Consistently, the treatment of propofol significantly repressed wound healing in SGC7901 and BGC823 cells (Figure 2C and D), indicating that propofol is able to attenuate the migration and invasion of gastric cancer cells. Consistently, propofol enhanced E-cadherin expression and reduced vimentin expression in SGC7901 and BGC823 cells (Figure 2E).

Propofol enhances ferroptosis in gastric cancer cells
To analyze the impact of propofol on ferroptosis, we assessed the role of propofol in the erastin-induced inhibition of cell growth and the intracellular levels of ROS, iron and Fe²⁺, and expression of GPX4 and SLC7A11, which are considered to be ferroptosis markers. Propofol enhanced the erastin-induced inhibitory effect on SGC7901 and BGC823 cell growth, in which erastin served as an activator of ferroptosis (Figure 3A and B). Iron levels were induced by propofol in SGC7901 and BGC823 cells (Figure 3C). Propofol significantly promoted the levels of ROS in SGC7901 and BGC823 cells (Figure 3D). Propofol increased accumulation of Fe²⁺ in SGC7901 and BGC823 cells (Figure 3E). Consistently, the expression of GPX4 and SLC7A11 was inhibited by propofol in SGC7901 and BGC823 cells (Figure 3F). GSH levels were reduced and MDA levels were enhanced in SGC7901 and BGC823 cells by treatment with propofol (Figure 3G and H), suggesting that propofol enhances ferroptosis in gastric cancer cells.

Propofol represses STAT3 expression by upregulating miR-125b-5p in gastric cancer cells
We explored the potential mechanisms underlying propofol-mediated gastric cancer progression. Given that propofol can regulate colon cancer metastasis by regulating STAT3 signaling[23], we assessed the correlation of propofol with STAT3 in gastric cancer. Significantly, we identified that propofol was able to upregulate expression of miR-125b-5p in SGC7901 and BGC823 cells (Figure 4A). We identified the binding site between miR-125b-5p and STAT3 mRNA 3’ UTR in a bioinformatic analysis using Targetscan (http://www.targetscan.org/vert_72/) (Figure 4B). Treatment with miR-125b-5p mimic reduced luciferase activities of wild-type STAT3, but not STAT3 with miR-125b-5p-binding site mutant in SGC7901 and BGC823 cells (Figure 4C and D). We confirmed whether propofol modulated ferroptosis by targeting STAT3 in gastric cancer cells. As expected, overexpression of STAT3 was able to rescue propofol-inhibited cell growth in the erastin-treated SGC7901 and BGC823 cells (Figure 5A). Similarly, STAT3 overexpression reversed propofol-induced levels of Fe²⁺, iron and ROS (Figure 5B-D), suggesting that propofol induces ferroptosis by inhibiting STAT3 in gastric cancer cells.

Propofol attenuates gastric cancer progression by miR-125b-5p/STAT3 axis
We further investigated the role of the propofol/miR-125b-5p/STAT3 axis in regulating gastric cancer malignant phenotypes. Overexpression of STAT3 or miR-
Figure 1 Propofol decreases proliferation and induces apoptosis of gastric cancer cells. A–E: SGC7901 and BGC823 cells were treated with propofol (10 µmol/L). A and B: MTT assays analyzed cell viability; C and D: Colony formation assays measured cell proliferation; E and F: Flow cytometry analysis tested cell apoptosis. n = 3, mean ± SD. *P < 0.01.
Propofol reduces invasion and migration of gastric cancer cells. A-D: SGC7901 and BGC823 cells were treated with propofol (10 µmol/L). A and B: Transwell assays analyzed cell migration and invasion; C and D: Wound healing assays examined migration and invasion. The wound healing proportion is shown. E: Protein levels of E-cadherin and vimentin were measured by western blotting. \( n = 3, \text{mean} \pm \text{SD}, ^{b}P < 0.01. \)

125b-5p inhibitor promoted propofol-inhibited viability in SGC7901 and BGC823 cells (Figure 6A and B). Consistently, apoptosis of SGC7901 and BGC823 cells was induced by propofol, and overexpression of STAT3 or miR-125b-5p inhibitor reversed this effect in SGC7901 and BGC823 cells (Figure 6C), implying that propofol has an inhibitor effect on gastric cancer malignant phenotypes via the miR-125b-5p/STAT3 axis. We confirmed that propofol-induced levels of Fe\(^{2+}\), iron and ROS were reversed by inhibition of miR-125b-5p in SGC7901 and BGC823 cells (Supplementary Figure 2).

Propofol attenuates growth of gastric cancer cells in vivo

We evaluated the effect of propofol on gastric cancer cell growth in a tumorigenicity analysis in nude mice. Tumor growth of SGC7901 or BGC823 cells was attenuated by propofol in nude mice (Figure 7A-C and Supplementary Figure 3A-C), as demonstrated by the reduced tumor size, weight and volume. As expected, expression of miR-125b-5p was enhanced and STAT3 expression was reduced in the tumor tissues of propofol-treated mice compared with the control group (Figure 7D and E and Supplementary Figure 3D and E). Expression of GPX4 and SLC7A11 was also down-regulated by propofol in the tumor tissues of mice (Figure 7F and Supplementary Figure 3F).

DISCUSSION

Gastric cancer is a prevalent malignancy with high mortality\([1]\), in which ferroptosis plays a critical role in its development\([6-8]\). Propofol is a widely used anesthetic and has inhibitory effects on cancer progression. Nevertheless, the effect of propofol on ferroptosis during the development of gastric cancer is still unreported. In this study, we showed that propofol induced ferroptosis and inhibited malignant phenotypes of gastric cancer cells by regulating the miR-125b-5p/STAT3 axis.

Propofol has presented significant anticancer functions in several models. It has been reported that propofol inhibits the development of nonsmall cell lung cancer by downregulating the miR215p/MAPK10 axis\([24]\). Propofol represses malignant progression of pancreatic cancer cells by reducing NMDA receptor\([25]\). Propofol induces apoptosis of cervical cancer cells through inhibition of the HOTAIr/mTOR pathway\([26]\). Moreover, it has been found that propofol represses proliferation, migration and invasion by enhancing miR-195 in gastric cancer cells\([14]\). Propofol improves cisplatin sensitivity in gastric cancer by MALAT1/miR-30e/ATG5 signaling via inhibiting autophagy\([27]\). Propofol suppresses the survival and growth of gastric cancer by inducing expression of ING3\([29]\). We found that propofol decreased proliferation, migration and invasion and induced apoptosis of gastric cancer cells. Importantly, propofol enhanced ferroptosis in gastric cancer cells. Our data indicate an unreported function of propofol in the modulation of ferroptosis during gastric cancer progression, elucidating the novel role of the anesthetic in the ferroptosis of cancer development. Ferroptosis is one of the critical malignant phenotypes mediated by propofol in gastric cancer progression. The importance of ferroptosis and apoptosis should be compared by more complex investigations. Meanwhile, it has been reported that the regulation of ferroptosis may benefit the inhibition of gastric cancer development, and targeting ferroptosis may be a promising strategy for gastric cancer therapy.
miRNAs function as crucial regulators and are involved in gastric cancer progression. It has been reported that miR-96-5p enhances gastric cancer cell proliferation via inhibiting FOXO3[29]. miR-27b inhibits gastric cancer metastasis by
Propofol represses signal transducer and activator of transcription (STAT)3 expression by upregulating miR-125b-5p in gastric cancer cells. A: SGC7901 and BGC823 cells were treated with propofol (10 µmol/L). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) measured expression of miR-125b-5p. B: The binding site of miR-125b-5p and STAT3 3'UTR was identified by bioinformatic analysis using Targetscan (http://www.targetscan.org/vert_72/). C-E: SGC7901 and BGC823 cells were treated with the miR-125b-5p mimic or control mimic. C and D: Luciferase reporter gene assays determined the luciferase activities. C: qRT-PCR analyzed mRNA expression of STAT3. F: SGC7901 and BGC823 cells were treated with propofol, or cotreated with propofol and miR-125b-5p inhibitor. Western blotting assessed protein expression of STAT3 and β-actin. n = 3, mean ± SD, bP < 0.01.

miR-125b-5p contributes to the progression of gastric cancer by repressing Smad4-regulated heparanase expression[31]. Moreover, it has been reported that miR-125b-5p represses invasion, migration and proliferation of breast cancer cells by inhibiting KIAA1522 [32]. miR-125b-5p suppresses invasion, migration and proliferation of hepatocellular carcinoma cell by downregulating thioredoxin reductase 1[33]. miR-125b-5p inhibits the progression of bladder cancer by attenuating PI3K/AKT signaling and targeting hexokinase 2[34]. In the present study, we found that propofol inhibited STAT3 expression by upregulating miR-125b-5p in gastric cancer cells. Propofol induced
LiuYP et al. Propofol induces ferroptosis of GC

Figure 5 Propofol enhances ferroptosis by targeting signal transducer and activator of transcription (STAT)3 in gastric cancer cells. A:

B:

C:

D:

Figure 5 Propofol enhances ferroptosis by targeting signal transducer and activator of transcription (STAT)3 in gastric cancer cells. A:
SGC7901 and BGC823 cells were treated with 5 mmol/L erastin, cotreated with 5 mmol/L erastin and propofol, or cotreated with 5 mmol/L erastin, propofol, and pcDNA.1-STAT3. MTT assays measured cell growth. B–D: SGC7901 and BGC823 cells were treated with propofol, or cotreated with propofol and pcDNA.1-STAT3. B: Iron Assay Kit analyzed the levels of iron; C: Flow cytometry analysis tested the levels of ROS; and D: Iron Assay Kit analyzed the levels of Fe²⁺. n = 3, mean ± SD, bP < 0.01, cP < 0.001.

Figure 6 Propofol attenuates gastric cancer progression by miR-125b-5p/STAT3 axis. A–C: SGC7901 and BGC823 cells were treated propofol, or cotreated with propofol and miR-125b-5p inhibitor or pcDNA.1-STAT3. A and B: MTT assays analyzed the cell viability; C: Flow cytometry measured apoptosis. n = 3, mean ± SD, bP < 0.01.

ferroptosis by targeting STAT3 in gastric cancer cells. The overexpression of STAT3 and miR-125b-5p inhibitor could reverse propofol-attenuated malignant phenotypes of gastric cancer cells. It uncovers a novel mechanism involving propofol, miR-125b-5p and STAT3 in the regulation of gastric cancer, enriching the understanding of the anticancer effect of propofol.

CONCLUSION

We discovered that propofol induced ferroptosis and inhibited malignant phenotypes of gastric cancer cells by regulating the miR-125b-5p/STAT3 axis. Propofol may serve as a potential therapeutic candidate for gastric cancer therapy.
Figure 7 Propofol attenuates growth of gastric cancer cells in vivo. The nude mice were injected with SGC7901 cells and intraperitoneally treated with propofol (50 mg/kg). A: Tumor tissues; B: Tumor volume; and C: Tumor weight; D: Expression of miR-125b-5p was analyzed by quantitative reverse transcription polymerase chain reaction. E: Protein expression of STAT3 was detected by western blotting. F: Protein expression of GPX4 and SLC7A11 was measured by western blotting. n = 5, mean ± SD, bP < 0.01.

ARTICLE HIGHLIGHTS

Research background
Gastric cancer is a common malignancy with poor prognosis, in which ferroptosis plays a crucial role in its development. Propofol is a widely used anesthetic and has shown antitumor potential in gastric cancer. However, the effect of propofol on ferroptosis during gastric cancer progression remains unreported.

Research motivation
This study aims to identify the function of propofol in the regulation of ferroptosis and malignant phenotypes of gastric cancer cells.

Research objectives
To explore the role of propofol in the regulation of ferroptosis and malignant phenotypes of gastric cancer cells.
Propofol may serve as a potential therapeutic candidate for gastric cancer therapy.

**REFERENCES**


Propofol induces ferroptosis of GC

[PMID: 30171944 DOI: 10.1016/j.jbiomac.2018.08.173]

Sayed D, Abbeldatif M. MicroRNAs in development and disease. Physiol Rev 2011; 91: 827-887

[PMID: 21742789 DOI: 10.1122/physrev.00006.2010]


